Long‐term Results of a Phase 1/1b Study of Ibrutinib Plus Umbralisib for Relapsed/refractory Chronic Lymphocytic Leukemia
HemaSphere（2025）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined